Cabotegravir/rilpivirine
Cabotegravir/rilpivirine, sold under the brand name Cabenuva, is a co-packaged antiretroviral medication for the treatment of HIV/AIDS. It contains cabotegravir and rilpivirine in a package with two separate injection vials.
| Combination of | |
|---|---|
| Cabotegravir | Integrase strand transfer inhibitor (INSTI) |
| Rilpivirine | Non-nucleoside reverse transcriptase inhibitor (NNRTI) |
| Clinical data | |
| Trade names | Cabenuva |
| AHFS/Drugs.com | Multum Consumer Information |
| MedlinePlus | a621009 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Intramuscular |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
The most common adverse reactions include injection site reactions, fever or feeling hot (pyrexia), fatigue, headache, musculoskeletal pain, nausea, sleep disorders, dizziness and rash.
The co-packaged medication was approved for medical use in the United States in January 2021. It is the first FDA-approved injectable, complete regimen for HIV-infected adults that is administered once a month. It is also approved for use in Canada. In the European Union, the two medications are approved separately.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.